Found 7 matching trials
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
PHASE2This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 ...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
PHASE2This is an open label, single arm, phase 2 trial investigating bezuclastini...
Status
Active Not Recruiting
Location
Sylvester Comprehensive Cancer Center, University of Miami
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
N/AThe purpose of this expanded access program (EAP) protocol is to provide in...
Location
Orso Health/Modena Asthma Allergy
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
PHASE2This is an open-label, two-part Phase 2 study investigating CGT9486 for the...
Location
University of Alabama at Birmingham (UAB) Hospital
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
PHASE3This is a Phase 3, open-label, international, multicenter study of CGT9486 ...
Location
University of Alabama at Birmingham
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
N/AThe purpose of this expanded access program (EAP) is to provide investigati...
Location
Mayo Clinic Hospital
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
PHASE1This is the first clinical trial of IDRX-42. The study is designed to evalu...
Status
Active Not Recruiting
Location
GSK Investigational Site